PF-Atlas › Clinical Trials › NCT04262635

Senolytics in Idiopathic Pulmonary Fibrosis

Dasatinib + Quercetin · Senolytics · Phase 2

Registry ID
NCT04262635
Phase
Phase 2
Status
Active, not recruiting
Drug / intervention
Dasatinib + Quercetin
Mechanism
Senolytics
Sponsor
Mayo Clinic
Start
2020-03

About this trial

Dasatinib + Quercetin is evaluated in NCT04262635, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Mayo Clinic, targeting senolytics. Current status: Active, not recruiting.

View NCT04262635 on ClinicalTrials.gov →

Explore related

Dasatinib + Quercetin — Treatment profileAll Dasatinib + Quercetin trialsSenolytics mechanismAll IPF trials

Related trials

Navitoclax — NCT05166694Fisetin — NCT04537533Dasatinib + Quercetin — NCT02874989
Medical disclaimer. This page summarizes public trial data for NCT04262635 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.